Phase 2 clinical trial: NSCLC atezolizumab given with usual chemo during radiation therapy

[NikoleV]

Brief Summary:

This phase II trial studies the effect of atezolizumab given with usual chemotherapy during radiation therapy in treating patients with superior sulcus non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, carboplatin, etoposide, paclitaxel and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving atezolizumab with usual chemotherapy and radiation therapy may lower the chance of the tumor from growing or spreading.

 

Here is a link to a patient-friendly summary from SWOG’s website:

http://swog.org/S1934

 

Here is a link to the clinical trial on NCI’s website, including study sites:

https://clinicaltrials.gov/ct2/show/NCT04989283

 

If you want more information, please contact the study investigator, Dr. Raymond Osarogiagbon, at rosarogi@bmhcc.org.